Bioverge is analyzing your deck using the same rigor as a sophisticated biotech investor.
Reading deck and identifying material claims
Auditing figures, legends and footnotes
Matching claims to supporting evidence
Evaluating translational gaps
Stress-testing competitive positioning
Assessing capital-to-de-risking efficiency
Simulating investor diligence
Verifying analysis




We examine the science, evidence, development strategy, commercial claims and financing narrative—surfacing what investors are likely to focus on.
Most analyses are completed within 2–5 minutes depending on deck length and complexity.
Your deck is not shared and is automatically removed according to our data retention policy.